• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Report from the Annual General Meeting of Olink Holding AB (publ) on 17 April 2023

    4/17/23 4:05:00 PM ET
    $OLK
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OLK alert in real time by email

    UPPSALA, Sweden, April 17, 2023 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 17 April 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com.

    Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liability

    The AGM adopted the Company's income statement and balance sheet and the consolidated income statement and consolidated balance sheet.

    The AGM resolved to dispose the Company's results in accordance with the Board of Directors' proposal, whereby no dividend will be paid for the financial year 2022 and that the Company's available funds be capitalized in a new account.

    The AGM also discharged the Board Members and the CEO from liability for the financial year 2022.

    Remuneration to the Board of Directors and Auditor

    The AGM decided, in accordance with the Nomination Committee's proposal, that the remuneration to the Board of Directors shall be distributed as follows: USD 120,000 to the Chair of the Board of Directors, USD 70,000 to each of the other Board Members appointed by the AGM who are not employed by the Company, additionally USD 20,000 to the Chair of the Remuneration Committee and additionally USD 10,000 to each other member of the Remuneration Committee, additionally USD 30,000 to the Chair of the Audit Committee and additionally USD 15,000 to each other member of the Audit Committee. Tommi Unkuri shall not receive any fees for Board or Committee work. Total fees amount to USD 640,000.

    The AGM decided that remuneration to the Auditor shall be paid according to approved invoices.

    Election of board members

    The AGM resolved, in accordance with the Nomination Committee's proposal, that the Board of Directors shall consist of nine Board Members and one Deputy Board Member. For the period until the end of the next Annual General Meeting the AGM re-elected the present Board Members Jon Hindar, Jon Heimer, Solange Bullukian, Johan Lund, Nicolas Roelofs, Mary Reumuth, Robert Schueren and Tommi Unkuri. Dr. Gregory J. Moore was elected as new Board Member. Furthermore, it was resolved to re-elect Jon Hindar as Chair of the Board of Directors.

    The AGM resolved, in accordance with the Nomination Committee's proposal, to re-elect Johan Pietilä Holmner as Deputy Board Member.

    Election of auditor

    The AGM resolved, in accordance with the Nomination Committee's proposal, to elect the registered audit firm Ernst & Young AB as auditor for the period until the end of the next Annual General Meeting. Ernst & Young AB has informed that Fredrik Norrman will be appointed as auditor in charge.

    Resolution on incentive program LTI I 2023 and issue of warrants and stock options

    The AGM resolved, in accordance with the Majority Shareholders' proposal, to adopt an additional Long Term Incentive program for the Board Members of the Company ("LTI I 2023").

    LTI I 2023 consists of stock options (with warrants as hedging arrangement). Upon exercise of all warrants issued within the frame of LTI I 2023, up to 70,000 shares (with reservation for any re-calculation) may be issued, equivalent to a maximum dilution of approximately 0.06 percent of the shares and votes of the Company. Upon full exercise of the warrants, the Company's share capital will increase with SEK 170,233.46.

    The calculations above have been based on the number of shares and votes in the Company as of the date of the notice.

    Resolution on incentive program LTI II 2023 and issue of warrants, stock options and restricted stock units

    The AGM resolved, in accordance with the Board of Directors' proposal, to adopt an additional Long Term Incentive program for the members of the group management, key employees, other employees and consultants of the Company and within the group ("LTI II 2023").

    LTI II 2023 consists of stock options and restricted stock units (with warrants as hedging arrangement). Upon exercise of all warrants issued within the frame of LTI II 2023, up to 910,000 shares (with reservation for any re-calculation) may be issued, equivalent to a maximum dilution of approximately 0.73 percent of the shares and votes of the Company. Upon full exercise of the warrants, the Company's share capital will increase with SEK 2,213,035.02.

    The calculations above have been based on the number of shares and votes in the Company as of the date of the notice.

    Authorization for the Board of Directors to decide on a new issue

    The AGM resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors, on one or several occasions until the next Annual General Meeting to resolve on issues of new shares, and that such new issue can be performed with deviation from the shareholders' preferential rights. The authorization may only be utilized to the extent that it corresponds to a dilution of not more than 20 percent of the total number of shares based on the number of shares outstanding at the time of the 2023 Annual General Meeting. Payment shall be able to be made in cash, in kind, by offset or otherwise in accordance with other conditions.

    For more information please contact:

    IR contact

    Jan Medina, CFA

    VP Investor Relations & Capital Markets

    Mobile: +1 617 802 4157

    [email protected]

    Media contact

    Andrea Prander

    Corporate Communications Manager

    Mobile: + 46 768 775 275

    [email protected]



    Primary Logo

    Get the next $OLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLK

    DatePrice TargetRatingAnalyst
    1/5/2023$27.00Sector Outperform
    Scotiabank
    12/14/2022$28.00Buy
    Canaccord Genuity
    2/14/2022$33.00 → $32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $OLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar

      6/6/23 8:00:00 AM ET
      $DNLI
      $DVA
      $EVLO
      $FHTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Misc Health and Biotechnology Services
      Biotechnology: Pharmaceutical Preparations
    • Bruno Rossi joins Olink as Chief Commercial Officer

      UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company's global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink. "I am delighted to welcome Bruno to the Olink organization, and look forward to the value his considerable industry experience will add to our rapidly growing company." said Carl Raimond, President of Olink. "Over the past two years, Olink has experienced remarkable growth. We have a

      3/21/23 8:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Financials

    Live finance-specific insights

    See more
    • Olink reports first quarter 2024 financial results

      UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 121, with 14 installations during the first quarterTotal Signature Q100 placements reached 202, with 16 placements during the first quarterExplore revenue of $18.0 million accounted for 63% of total first quarter revenue, with Explore Kit revenue totaling $11.3 million, or 63% of t

      5/13/24 6:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024

      UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liabilityThe AGM adopted the Company's income statement and balance sheet and the consolidated income statement an

      4/19/24 4:05:00 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Olink reports fourth quarter and full year 2023 financial results

      UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basisFull year revenue 2023 revenue totaled $169.6 million, achieving year over year growth of 21% on a reported basis and 21% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 107, with 20 installations during the fourth quarterTotal Signature Q100 placements reached 186, wit

      3/25/24 8:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $OLK
    SEC Filings

    See more
    • Notice to attend the Extra General Meeting of Olink Holding AB (publ)

      This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eur

      7/11/24 4:05:45 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

      Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research

      7/10/24 8:00:00 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

      UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis

      7/8/24 7:37:45 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • SEC Form 15F-12B filed by Olink Holding AB

      15F-12B - Olink Holding AB (publ) (0001835539) (Filer)

      7/22/24 5:19:56 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 6-K filed by Olink Holding AB

      6-K - Olink Holding AB (publ) (0001835539) (Filer)

      7/22/24 8:30:04 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 14D9/A filed by Olink Holding AB

      SC 14D9/A - Olink Holding AB (publ) (0001835539) (Subject)

      7/17/24 8:30:07 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Olink Holding with a new price target

      Scotiabank initiated coverage of Olink Holding with a rating of Sector Outperform and set a new price target of $27.00

      1/5/23 7:46:07 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Canaccord Genuity initiated coverage on Olink Holding with a new price target

      Canaccord Genuity initiated coverage of Olink Holding with a rating of Buy and set a new price target of $28.00

      12/14/22 8:56:12 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Olink Holding with a new price target

      Morgan Stanley reiterated coverage of Olink Holding with a rating of Equal-Weight and set a new price target of $32.00 from $33.00 previously

      2/14/22 8:24:48 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Olink Holding AB (Amendment)

      SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)

      2/14/24 10:03:04 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Olink Holding AB

      SC 13G - Olink Holding AB (publ) (0001835539) (Subject)

      2/9/24 7:59:50 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Olink Holding AB (Amendment)

      SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)

      11/13/23 9:02:39 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials